“…The BET family proteins, especially BRD4, have recently been shown to play an important role in the pathways that cause multiple types of cancer, including acute myeloid leukemia (Zuber et al, 2011), mixed lineage leukemia (Dawson et al, 2011), multiple myeloma (Mertz et al, 2011), and an aggressive form of squamous carcinoma called NUT (nuclear protein in testis) midline carcinoma (Filippakopoulos et al, 2010; French et al, 2008; French et al, 2001; French et al, 2003; Reynoird et al, 2010). These clinically relevant studies have validated the BET bromodomains as attractive epigenetic cancer therapy targets, and also displayed the need for potent and selective bromodomain inhibitors (Belkina and Denis, 2012; Furdas et al, 2012; Muller et al, 2011). …”